"HLA-A Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
| Descriptor ID |
D015234
|
| MeSH Number(s) |
D12.776.395.550.489.400 D12.776.543.550.439.400 D23.050.301.500.100.400 D23.050.301.500.450.370 D23.050.705.552.100.400 D23.050.705.552.450.370
|
| Concept/Terms |
HLA-A Antigens- HLA-A Antigens
- HLA A Antigens
- HLA-A
- Antigens, HLA-A
- Antigens, HLA A
|
Below are MeSH descriptors whose meaning is more general than "HLA-A Antigens".
Below are MeSH descriptors whose meaning is more specific than "HLA-A Antigens".
This graph shows the total number of publications written about "HLA-A Antigens" by people in this website by year, and whether "HLA-A Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HLA-A Antigens" by people in Profiles.
-
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology. 2018 01 23; 90(4):e332-e341.
-
The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. Int J Cancer. 2009 Nov 15; 125(10):2474-8.
-
Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res. 2008 Oct 15; 14(20):6574-9.
-
Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. Blood. 2007 Oct 15; 110(8):2931-9.
-
Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer. 2005 Jun 10; 115(2):333-6.
-
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood. 2003 Nov 01; 102(9):3287-94.
-
Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy. J Immunother. 2003 May-Jun; 26(3):257-69.
-
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 01; 168(11):5900-6.
-
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999 Jun; 10(6):673-9.
MeSH information
